Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Monthly Prescribing Reference1y
Abilify Asimtufii
Patients receiving Abilify Maintena: 960mg once every 2 months; may administer in place of next scheduled inj; reduce to 720mg once every 2 months if adverse reactions occur. Dose adjustments for ...
pharmaphorum2d
Abilify MyCite and innovating in digital health
Two companies that have been blazing a trail in this field are Otsuka Pharmaceutical Company and Proteus Digital Health, with the co-developed Abilify MyCite (aripiprazole tablets with sensor ...
Proposed Settlement Reached in the Canadian ABILIFY® and ABILIFY MAINTENA® Class Actions
A proposed Settlement has been reached on behalf of all individuals in Canada who were prescribed and took ABILIFY® before February 23, 2017 ("ABILIFY® Class Members") and/or received injections of ...
pharmaphorum4d
Former CEO of Proteus reflects on the dramatic fall of 'digital pill' unicorn
Together with Japan's Otsuka Pharmaceuticals, the company produced the ground-breaking smart pill Abilify Mycite (aripiprazole). But the partnership ran into trouble after poor uptake by payers in ...
BBC7y
FDA approves 'trackable' pill
US regulators have approved the first pill that can be digitally tracked through the body. The Abilify MyCite aripiprazole tablets - for treating schizophrenia and manic episodes - have an ...
H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024
Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Key highlights Lundbeck's total revenue grew by +13% CER[1] (+10% DKK) to DKK 16,463 milli ...